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Abstract: Malignant gliomas consist of glioblastomas, anaplastic astrocytomas, anaplastic 
oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such as 
anaplastic ependymomas and anaplastic gangliogliomas. Malignant gliomas have high mor-
bidity and mortality. Even with optimal treatment, median survival is only 12–15 months for 
glioblastomas and 2–5 years for anaplastic gliomas. However, recent advances in imaging and 
quantitative analysis of image data have led to earlier diagnosis of tumors and tumor response 
to therapy, providing oncologists with a greater time window for therapy management. In 
addition, improved understanding of tumor biology, genetics, and resistance mechanisms has 
enhanced surgical techniques, chemotherapy methods, and radiotherapy administration. After 
proper diagnosis and institution of appropriate therapy, there is now a vital need for quantitative 
methods that can sensitively detect malignant glioma response to therapy at early follow-up 
times, when changes in management of nonresponders can have its greatest effect. Currently, 
response is largely evaluated by measuring magnetic resonance contrast and size change, but 
this approach does not take into account the key biologic steps that precede tumor size reduc-
tion. Molecular imaging is ideally suited to measuring early response by quantifying cellular 
metabolism, proliferation, and apoptosis, activities altered early in treatment. We expect that 
successful integration of quantitative imaging biomarker assessment into the early phase of 
clinical trials could provide a novel approach for testing new therapies, and importantly, for 
facilitating patient management, sparing patients from weeks or months of toxicity and ineffec-
tive treatment. This review will present an overview of epidemiology, molecular pathogenesis 
and current advances in diagnoses, and management of malignant gliomas.
Keywords: glioblastoma multiforme, malignant gliomas, MRI, PET, FLT, early therapy response 
assessment, quantitative molecular imaging
Epidemiology and classification of brain tumors
The estimated number of new cases (adjusted for age) using the world standard 
 population of primary malignant brain and central nervous system cancer in 2008, 
was 3.8 per 100,000 in males and 3.1 per 100,000 in females. The incidence rates were 
higher in more developed countries (males: 5.8 per 100,000; females: 4.4 per 100,000) 
than in less developed countries (males: 3.2 per 100,000; females: 2.8 per 100,000).1 In 
the US, the annual incidence of primary malignant gliomas is approximately five cases 
per 100,000 people.2,3 Every year, about 22,500 new cases of malignant primary brain 
tumor are diagnosed in adults in the US, out of which 70% are malignant gliomas.2,3 
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Glioblastomas account for approximately 60% to 70% of 
malignant gliomas, anaplastic astrocytomas for 10% to 
15%, and anaplastic oligodendrogliomas and anaplastic 
oligoastrocytomas for 10%; less common tumors, such as 
anaplastic ependymomas and anaplastic gangliogliomas, 
account for the rest.2,3
The World Health Organization (WHO) classif ies 
 astrocytomas based on histologic type,2,4 with grading based 
on the most malignant region of the tumors. Tumor grade 
depends upon the degree of nuclear atypia, mitotic activity, 
microvascular proliferation, and necrosis, with increased 
anaplasia corresponding to higher tumor grade. Grades 
include low-grade, or WHO grade I (pilocytic astrocytoma) 
and grade II (diffuse astrocytoma); and high-grade, or WHO 
grade III (anaplastic astrocytoma) and grade IV (glioblastoma 
multiforme, GBM). Grade III and IV tumors are considered 
malignant gliomas. The median age at the time of diagnosis 
is 64 years for glioblastomas and 45 years in the case of 
anaplastic gliomas.5
Apart from primary brain tumors, brain metastases 
from common solid tumors that spread to the brain primar-
ily include those of lung, breast, and melanoma. However, 
a recent increase in the incidence of brain metastases from 
other cancer types, such as renal, prostate, and colorectal 
cancers, has been observed.6,7
Molecular pathology
Molecular pathology of primary  
brain tumors
In the past 2 decades, the application of molecular pathology in 
diagnosis and classification has transformed the management 
of malignant gliomas.8 Molecular biomarkers have been able 
to differentiate oligodendroglial tumors from astrocytomas, 
resolve controversies regarding classification of mixed 
oligoastrocytic tumors, and identify clinically significant 
subgroups of anaplastic astrocytoma and glioblastoma.9,10 
Recent clinical pathologic correlations between outcome 
and molecular biomarkers have also validated predictive 
markers for oligodendrogliomas and identified subgroups of 
glioblastoma susceptible to epidermal growth factor receptor 
(EGFR) signal transduction inhibitors.11–13
The European Organization for Research and Treatment 
of Cancer has identified six different types of anaplastic oli-
godendrogliomas using microarray unsupervised gene expres-
sion analysis of the tumor specimens obtained as part of the 
European Organization for Research and Treatment of Cancer 
trial (EORTC 26951).13 These intrinsic molecular subtypes had 
prognostic significance for progression-free survival (PFS) 
independent of the previously recognized prognostic factors, 
including 1p/19q deletion, isocitrate dehydrogenase gene 
(IDH1) mutation, and O6-methylguanine-DNA-methyltrans-
ferase (MGMT) promoter methylation status. One subgroup, 
with a 1p/19q deletion and IDH1 mutation, especially ben-
efitted from the addition of chemotherapy to external beam 
radiation, demonstrating an overall survival (OS) of 12.8 years 
with adjuvant chemotherapy contrasted with 5.5 years for those 
patients treated with radiation alone.
It is now recognized that patients with oligodendroglial 
tumors with 1p/19q deletions have a consistently better prog-
nosis for survival than those with tumors of equivalent grade 
and similar histologic appearance that lack the deletions.14,15 
In two recently reported prospective randomized trials of 
fractionated external beam radiotherapy (EBRT) with or 
without alkylator-based chemotherapy for newly diagnosed 
anaplastic astrocytoma, the presence of 1p deletions was 
a predictive marker for the cohort of patients in which the 
addition of chemotherapy led to prolonged OS.11
The identification of mutations in isocitrate dehydro-
genase (IDH) isoenzymes 1 and 2 in a high percentage of 
low grade gliomas and in subsets of anaplastic astrocytoma, 
oligodendroglioma, and glioblastoma has further refined 
the delineation of prognosis. IDH1 is a good prognostic 
marker for anaplastic astrocytoma and glioblastoma.9,16 For 
anaplastic astrocytoma, lack of an IDH1 mutation appears to 
identify a subgroup of histologically indistinguishable tumors 
with a prognosis similar to glioblastoma.17 The oncogenic 
mechanism appears to be the production of a metabolite, 
2-hydroxyglutarate (2HG), which inhibits ketoglutarate-
dependent dioxygenases, leading to aberrant histone and 
DNA methylation.16
In clinical trials of alkylator-based chemotherapy 
regimens for glioblastoma, anaplastic astrocytoma, and 
oligodendroglioma,9,18 the MGMT promoter methylation 
status has proven to be a prognostic, though not a specific 
predictive biomarker. Hegi et al demonstrated that promoter 
methylation silencing of the MGMT gene correlates strongly 
with long-term survival in patients receiving chemotherapy.19 
At the same time, Brandes et al showed that for patients 
receiving chemoradiation for newly diagnosed GBM, MGMT 
promoter methylation silencing correlates with increased 
frequency of vascular permeability of vessels in the radia-
tion treatment field.20 This may produce a transient increase 
in the volume of contrast taken up by the lesion, known as 
“pseudoprogression”.20
GBMs that arise de novo appear to be different genetically 
from those that arise from prior low-grade astrocytomas.9 
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IDH and p53 mutations are rare in primary GBM. In contrast, 
primary GBMs are characterized by EGFR amplification 
and mutation, loss of heterozygosity on chromosome 10q, 
and inactivation of the phosphatase and tensin homolog 
(PTEN) gene.21 Secondary GBMs are characterized by tumor 
protein p53 (TP
53
) mutations and platelet-derived growth 
factor receptor activation.21 A poor prognosis subgroup of 
secondary GBM in older adults, in which relapse occurs in 
the first year after treatment, appears to be characterized by 
lack of IDH1 mutations, similar to primary GBM’s molecular 
signature.22
Microarray-based unsupervised genome-wide analysis 
of gene expression in glioblastomas has identified at least 
four subgroups differentiable by molecular profile.23 Phillips 
et al examined 107 grade III and IV astrocytomas, and using 
a set of 35 signature genes, segregated into three subtypes: 
proneural, proliferative, and mesenchymal.24 In this study, the 
proneural subset had a better prognosis than the proliferative 
and mesenchymal subsets, which had worse prognoses.
The investigators of The Cancer Genome Atlas (TCGA) 
pilot project25 proposed a four-subgroup classification based 
on analysis of 202 GBMs. The subtypes include proneural, 
neural, classical, and mesenchymal. In the context of the 
cancer genome atlas, Noushmehr et al profiled promoter 
DNA methylation alterations in 272  glioblastomas (43 
low and intermediate grade gliomas and 57 additional 
primary GBMs).26 They reported a distinct subset of tumors 
with increased DNA methylation at large number of loci, 
indicating the existence of a glioma–CpG island methy-
lator  phenotype (G–CIMP).26 Within the GBM cohort, 
the G–CIMP phenotype correlates with IDH1 mutation, 
younger age, proneural genotype, and a better prognosis.
The EGFR gene is the most frequently amplified gene 
in primary GBM and is seen in 94% of the TCGA classical 
type,25 and in the proliferative and mesenchymal subtypes 
in the Phillips classification.24 A specific in-frame deletion 
of exons 2–7 is present in 20%–30% of GBM overall and 
50%–60% of GBM with EGFR gene amplification.27 The 
protein product of this truncated mRNA is the EGFRvIII 
mutant protein. This protein is the target antigen for immu-
notherapy strategies, including vaccines. Although the 
small molecule EGFR tyrosine kinase inhibitors trials for 
patients with GBM and anaplastic astrocytoma demonstrated 
low response rates and no benefit in PFS, a small subset 
of patients had durable responses.28 A specific genotype 
correlated with response in which EGFRvIII mutation was 
present in the context of intact AKT pathway function, with 
wild-type PTEN.29
BRAF (an oncogene located on chromosome 7) encodes 
a serine threonine kinase involved in cell signaling, and also 
involved in mitogen-activated protein kinases/extracellular 
signal regulated kinases pathway activation, and cell growth is 
most commonly associated with low-grade pediatric gliomas, 
but is commonly seen in high-grade diffuse gliomas as well. The 
most common BRAF abnormalities involve gene duplication 
with fusions leading to a mutant protein with a constitutively 
active kinase domain.9 Mutation in p53 and BRAF appear to be 
mutually exclusive.30 The presence of activating BRAF muta-
tions may identify a therapeutic target in the high-grade gliomas 
in which it is expressed. BRAF inhibitor vemurafenib is US 
Food and Drug Administration (FDA)-approved as treatment 
for melanoma with BRAFV600E mutation.31
Molecular markers are also useful to predict a response 
to chemotherapy in three settings: 1p and 19q loss, MGMT 
methylation, and possibly the EGFR–PI3 kinase pathways in 
response of glioblastomas to specific EGFR inhibitors.
1p and 19q deletions
Allelic loss of chromosomes 1p and 19q is a powerful pre-
dictor of chemotherapeutic response and longer PFS and 
OS following chemotherapy with either temozolomide or 
procarbazine, lomustine, and vincristine (PCV) in patients 
with anaplastic oligodendrogliomas. Those tumors with 1p 
and 19q loss in the setting of polysomy of chromosomes 1 and 
19 have intermediate prognoses. Allelic loss of 1p alone 
is also predictive of response to temozolomide in patients 
with grade II oligodendroglial tumors.32 Thus, testing for 1p 
and 19q status is now widespread and is used to influence 
therapeutic decisions.
MGMT promoter methylation
In the course of tumor development, the MGMT gene may be 
silenced by methylation of its promoter, thereby  preventing 
repair of DNA damage and increasing the potential effec-
tiveness of chemotherapy. Several clinical studies have 
indicated that such promoter methylation is associated with 
an improved survival in patients receiving adjuvant alkylating 
agent chemotherapy.33
eGFR-Pi3 kinase pathways
Two studies evaluated patients with glioblastomas treated 
with the EGFR inhibitors, erlotinib or gefitinib34,35 and found 
that, in contrast to other studies that did not report objective 
responses,36 patients with recurrent glioblastoma responded 
to these two agents. Furthermore, the studies showed asso-
ciations between response and activation of EGFR itself 
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(one report implicating the wild-type receptor34 and the other 
implicating the vIII mutant EGFR35), as well as between 
response and whether the PI3 kinase pathway was function-
ally intact (one report measuring phosphorylated AKT and 
the other measuring PTEN expression). If responses continue 
to be documented with these agents, immunohistochemical 
testing for EGFR and the PI3K pathway may prove useful.
Molecular pathology of brain metastases
The pathophysiology of brain metastasis is complex and 
distinct from primary brain tumors. It is dependent upon 
both oncogenic processes and host organ responses. Some 
of the multiple mechanisms that ultimately determine the 
development of a brain metastasis include, but are not limited 
to, the phenotype of the brain-trophic tumor cells, tumor cell 
survival in the vasculature and extravasation of those cells 
from the bloodstream and into a host organ, and the structure 
and function of the blood–brain barrier (BBB).
Since the brain does not contain lymphatics, circulating 
tumor cells reach the brain parenchyma only via a hemato-
genous route. Invading metastatic cancer cells interact with all 
cell types, including endothelium, pericytes, and astrocytes, to 
breach the BBB and gain access to brain parenchyma.37 Once 
tumor cells enter the brain parenchyma, a number of factors 
are released by both the tumor cells and the underlying brain. 
In co-culture experiments, lung-cancer-derived cells release 
tumor-associated factors, including macrophage migration 
inhibitory factor, interleukin-8, and plasminogen activator 
inhibitor-1, which stimulate astrocytes. In turn, the activated 
astrocytes release interleukin-6, tumor necrosis factor-α, and 
interleukin-1β, which induce tumor cell proliferation.38,39
Receptor biomarkers indicating an enhanced potential for 
the development of central nervous system metastases may be 
identified in the primary tumor cell and thereby define future 
therapeutic targets. For example, overexpression of human 
epidermal growth factor receptor 2 (HER2/neu) is predictive of 
a three-fold increase in metastases to the lungs, liver, and brain 
as compared with HER2/neu-negative breast carcinomas.40–42 In 
lung adenocarcinoma, genetic alterations in homeobox protein 
Hox-B9 and lymphoid enhancer-binding factor 1 lead to hyper-
activity of the Wnt/T Cell Factor (Wnt/TCF) pathway, which has 
been implicated in the growth of cancer stem cells and enhanced 
competence to metastasize to the bone and brain.43,44
Diagnosis
Clinical signs and symptoms
Although the symptoms and signs produced by malignant 
gliomas will vary with the location of the tumor, a unifying 
characteristic of the clinical presentation is relentless 
progression. For tumors that are located in or subjacent to corti-
cal regions with specific functions, the symptoms and signs will 
relate to the functions of the brain regions affected. Patients may 
present with progressive motor or sensory disturbances, lan-
guage dysfunction, visual field abnormalities, or focal seizures. 
Tumors arising in the brain stem may cause rapidly progress-
ing cranial neuropathies as well as motor and sensory deficits. 
Neurologic deficits with less localizing features may include 
headache, confusion, memory loss, and personality changes.
As the size of tumor increases, the edema surrounding 
the tumor increases, resulting in increased intracranial pres-
sure and subsequent headaches. The headaches associated 
with increased intracranial pressure are typically worse 
when the patient is recumbent. When intracranial pressure 
rises to a critical threshold, changes in blood pressure due to 
dysfunctional autonomic reflexes may produce a syndrome 
of position-evoked crescendo headache, visual obscurations, 
lightheadedness, and exacerbation of focal symptoms. This 
cluster of symptoms is associated with intracranial pressure 
waves and is usually associated with papilledema.
Neuroimaging
Neuroimaging plays a crucial role in diagnosing and assess-
ing the location, extent, and biologic activity of the tumor 
before, during, and after treatment. Its role in low-grade 
tumors lies in the monitoring of possible recurrent disease 
or anaplastic transformation into high-grade tumors. In high-
grade tumors, neuroimaging is much needed for differentiat-
ing recurrent tumor from treatment-induced changes such as 
radiation necrosis.
Gliomas are often characterized by diffuse infiltration 
of white matter tracts,45 and stereotactic biopsy studies have 
demonstrated that these regions appear normal on conven-
tional contrast-enhanced computed tomography (CT) and 
magnetic resonance imaging (MRI).46 Since complete resec-
tion of infiltrative high-grade neoplasms is not an option,47 
the development of improved posttreatment imaging to detect 
residual tumor is pivotal in clinical outcome.
MRI serves as the current gold standard in tumor treat-
ment response monitoring; however, prognostic informa-
tion cannot be obtained until weeks after the initiation of 
treatment.48 Determination of recurrence versus treatment 
effects on CT or MRI cannot be accurately evaluated.49–51 
Functional imaging can distinguish cerebral necrosis from 
viable brain tumor, and determine viability grade.52–54
The realization that the MacDonald criteria1 for response 
assessment in clinical trials of treatments for high-grade 
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gliomas failed to account for nonenhancing progression has 
led to the development of a new paradigm, the Response 
Assessment for Neuro-Oncology (RANO) criteria.55 
Differentiating tumor response related to cytotoxicity from 
physiologic modifications of BBB function is a major focus 
of translational imaging research. MRI techniques that 
interrogate the vascular density and permeability of tumor 
vasculature as well as positron emission tomography (PET) 
techniques56 are being evaluated as imaging biomarkers 
of tumor response in treatment trials of anti-angiogenic 
therapy.57
CT
Most of the time, CT is the first imaging modality for 
evaluating symptoms of gliomas. Contrast-enhanced CT 
scans can delineate disruptions in the BBB, but CT sen-
sitivity is much lower than that of MRI. The attenuation 
difference can offer limited information on tumor biology. 
For instance, slightly increased tissue density during tumor 
monitoring may indicate increase in tissue cellularity, or 
tumor growth. On the other hand, decreased attenuation 
in the treated region indicates low tumor cellularity or 
edema. However, the exact delineation of tumor borders 
or the extent of treatment-related changes is not feasible 
using this modality.
MRi
The clinical gold standard for brain tumor imaging, MRI, 
utilizes T1- and T2-weighted sequences, fluid-attenuated 
inversion recovery sequences, and contrast-enhanced 
T1-weighted imaging for tumor monitoring. Glioblastoma is 
classically hypointense to isointense, with a ring-pattern of 
enhancement on gadolinium-enhanced T1-weighted images, 
and is hyperintense on both T2-weighted and FLAIR (fluid-
attenuated inversion recovery) images ( Figure 1).58,59 It can 
be focal, multifocal, or diffuse (gliomatosis cerebri).
MRI provides excellent anatomic detail; however, it 
cannot reliably differentiate between radiation necrosis and 
recurrence posttreatment (Figure 2).60,61 This is of critical 
importance in monitoring tumor response to chemoradiation 
and stereotactic radiosurgery, both of which are associated 
with high prevalence of post-therapy necrosis.
Although BBB destruction with subsequent leakage 
of contrast medium is commonly seen in most high-grade 
tumors, such as glioblastomas, it is not a reliable distinguish-
ing feature of tumor grade.62 In fact, approximately one-
third of nonenhancing gliomas are malignant.63 Moreover, 
glioblastoma may initially present as a nonenhancing lesion, 
especially in older patients. In addition, contrast enhancement 
cannot always be used to assess response since therapy may 
result in BBB disruption without a corresponding change in 
tumor status.64,65
After therapy, physiologic MRI can provide insights 
into changes in tumor environment related to metabo-
lism  (magnetic resonance spectroscopy [MRS]), perfu-
sion (perfusion-weighted imaging), and microstructure 
( diffusion-weighted imaging [DWI]). Indeed, apparent 
 diffusion coefficient (ADC) measurements,66–68 DWI values,69 
and fluid-attenuation inversion recovery images70 correlate 
with the probability of response to therapy.
1H MRS
The magnetic resonance spectrum from 1H MRS contains 
peaks representative of different (hydrogen-containing) 
metabolites. The relative concentration of each metabolite 
is determined from the area under the corresponding peak. 
Whereas single-voxel spectroscopy yields a single spectrum 
Figure 1 Magnetic resonance findings in GBM.
Notes: (A) T1 pre-contrast images exhibit a hypointense lesion in the left frontal 
lobe region (arrow). (B) Axial T1 post-contrast images, after injection of 20 cc of 
intravenous MultiHance®, demonstrate a focus of enhancement in left frontal lobe. 
(C) Axial T2 FLAiR images show increase in FLAiR signal in the left frontal lobe, 
which demonstrates enhancement. (D) T2 FSe images also demonstrate increase in 
signal in the region of the left frontal lobe.
Abbreviations: FLAiR, fluid-attenuated inversion recovery; FSE, fast spin-echo; 
GBM, glioblastoma multiforme.
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from a defined tissue area, two- and three-dimensional 
chemical shift imaging depict one or more tissue slices 
with several voxels in each slice to better account for tissue 
inhomogeneities.
In the case of tumor monitoring, tumor metabolite data 
are compared to those of the contralateral healthy side. The 
most commonly examined metabolites include lactate as a 
product of anaerobic glycolysis,71 N-acetylaspartate as a sign 
of neuronal viability and density,72,73 choline as an indicator 
of high membrane turnover and thus cell proliferation,74,75 
and creatine as a signature of cell energy expenditure used 
for an internal reference value.76 Increasing choline/creatine 
ratios and lactate concentrations,75 and decreasing N-acety-
laspartate77 correlate with tumor progression, and can also 
be seen in tumor recurrence (Figure 3). Whereas elevated 
creatine values (normalized to normal brain) correlate 
with a shorter time-to-progression in WHO grade II and III 
astrocytomas,78,79 no correlation was identified between tumor 
grading and choline/creatine ratio.80
A study by Imani et al compared the accuracy of high-
field proton MRS (1H MRS) and 18F 2-fluorodeoxyglucose 
PET (18F-FDG PET) for identification of viable tumor recur-
rence in 12 grade II and III glioma patients and showed that 
1H MRS imaging was more accurate in low-grade glioma 
and 18F-FDG PET provided better accuracy in high-grade 
gliomas.80 The study also suggested that the combination 
of 1H MRS data and 18F-FDG PET imaging can enhance 
detection of glioma progression. While the sensitivity of 
18F-FDG PET in detecting glioma progression was very 
high (100%), its specificity in differentiating post-therapy 
Figure 2 Radiation necrosis versus viable tumor on MRi.
Notes: Sixty-nine-year-old male with glioblastoma multiforme, status post-chemotherapy presented with dizziness. Contrast MRi and 18F-FDG PeT were performed to 
evaluate for progression. Post-contrast T1 MR (A) is suggestive of rim enhancement of tumor (arrow). 18F-FDG PeT (B) and PeT-MR fusion (C) images show an area of 
relatively decreased activity corresponding to the area of rim enhancement. PET findings were diagnostic for nonviable tissue. In this case, MR was unable to differentiate 
between radiation changes and viable tumor. 
Abbreviations: FDG, 2-fluorodeoxyglucose; MR, magnetic resonance; MRI, magnetic resonance imaging; PET, positron emission tomography.
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inflammation from true tumor progression was low (71%), 
leading to a high false positive rate (29%) in post-radiation 
therapy patients.
Studies have looked into the significance of IDH muta-
tional status in the diagnosis and classification of gliomas 
and the identification of an oncometabolite, 2HG, which 
accumulates in IDH mutant tumors.9,16 Recent investigations 
using ultrahigh field strength MRI suggest that the presence 
of IDH mutations in a tumor can be noninvasively detected 
by spectroscopic measurement of 2HG.81 Recently, investi-
gators in the US and Europe have demonstrated that MRS 
can differentiate 2HG from neighboring metabolites, such 
as gamma amino butyric acid, glutamine, and glutamate. 
Kalinina et al82 analyzed brain tumor specimens to show 
the feasibility of using MRS to quantitate 2HG for the 
classification of IDH mutant tumors. Subsequently, Pope 
et al83 demonstrated detection of 2HG by MRS in glioma 
patients prior to resection, with analysis of IDH1 status by 
DNA sequencing, and measurement of concentrations of 
2HG and other metabolites by liquid chromatography–mass 
spectroscopy. In tumors with IDH1 mutations, 2HG levels, 
as measured in vivo using water suppressed proton (1H) 
MRS, correlate with measured amounts in the resected tumor 
specimens. Tumors with IDH1 mutations have elevated 
choline and decreased glutathione levels. Elkhaled et al81 
also demonstrated that levels of 2HG correlate with levels 
of choline, lactate, and glutathione, as well as with histo-
pathologic grade. While it appears that MRS can provide 
a noninvasive measure of 2HG in human gliomas, further 
studies are needed to validate the utility of 2HG quantita-
tion and the relevance of other alterations in metabolites as 
prognostic biomarkers.
Dwi-MRi
DWI relies on the microscopic motion of water molecules 
within tissue. The process is influenced by temperature and 
tissue architecture84 and is commonly quantified by the 
ADC. Tumor infiltration alters tissue architecture and thus 
water  diffusion. ADC decreases with an increase in viscos-
ity, cellular density, and reduction of extracellular space. 
Low values in ADC maps in solid gliomas are associated 
with higher-grade tumors.85 Complicating the interpretation 
is coexistent posttreatment edema which may alter ADC 
values. The recently introduced higher-order diffusion 
technique, diffusion kurtosis imaging,86 is being studied 
to characterize microstructural changes, and initial find-
ings appear  promising in the differential diagnosis of brain 
tumors.87
Perfusion-weighted MRi
Perfusion-weighted imaging involves the quantification of 
cerebral blood volume (CBV) after contrast administra-
tion with a dynamic MRI sequence sensitive to T2* effects. 
A graph of contrast enhancement is generated to calculate the 
area under the signal curve as an estimate of relative CBV 
(rCBV). High-grade gliomas, in particular, are associated 
with disruption of the BBB, which causes more contrast 
extravasation and consequent adjustments to rCBV calcula-
tions with sophisticated mathematical models.88 Preloading 
of contrast medium has been applied to minimize the effects 
of leakage.89,90 Increased angiogenesis in high-grade gliomas 
is also correlated with higher CBV relative to contralateral 
normal white matter rCBV and tumor aggressiveness.91–93 
Quantitative analysis found a threshold of rCBV =1.75 for 
determining a high-grade glioma91 and a higher rCBV ratio 
of about 2.14 for  oligodendrogliomas.94 It has also been 
shown that an increase in rCBV occurs up to 12 months prior 
to malignant transformation as assessed by new contrast 
enhancement.95
Figure 3 Magnetic resonance spectroscopy.
Notes: Anaplastic astrocytoma, wHO grade iii. Multiple-voxel spectra coregistered 
with post-contrast T1-weighted MRi (A). Map of Cho/Cr demonstrates a focus of signal 
intensity in the right frontal lobe (B). MRSi signal intensity is presented on a rainbow 
color scale where blue-green is normal background and bright red corresponds to 
greatly elevated signal intensity. Spectral analysis of the voxel demonstrating maximal 
Cho/Cr ratio (C). T1-weighted MRi (post-contrast) demonstrating enhancing lesion in 
the right frontal lobe (D). 18F-FDG PeT scan shows a focus of increased tracer activity 
greater than white matter in the right frontal lobe (E). 18F-FDG PeT image coregistered 
with post-contrast T1-weighted MRi (F). Reproduced with permission from John wiley 
and Sons. imani F, Boada Fe, Lieberman FS, Davis DK, Deeb eL, Mountz JM. Comparison 
of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose 
positron emission tomography for assessment of brain tumor progression. J Neuroimaging. 
2012;22(2):184–190.80 Copyright © 2010 by the American Society of Neuroimaging.
Abbreviations: Cho/Cr, choline/creatine; MRi, magnetic resonance imaging; MRS, 
magnetic resonance spectroscopy; NAA, N-acetylaspartate; wHO, world Health 
Organization; FDG, 2-fluorodeoxyglucose; PET, positron emission tomography.
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PeT
imaging glucose metabolism – 18F-FDG
18F-FDG PET has allowed monitoring of therapeutic response 
in brain tumors with a greater specificity than CT or MRI. 
18F-FDG, a glucose analog, is taken up by high-glucose-
using cells, including normal brain and cancer cells. FDG 
is actively transported across the BBB into the cell and the 
18F-FDG-6-phosphate formed when 18F-FDG enters the cell 
and prevents its further metabolism. As a result, the distri-
bution of 18F-FDG is a good reflection of the distribution of 
glucose uptake and utilization by cells in the body.
Since most cancer cells, including gliomas, demonstrate 
a high rate of glycolysis,96 18F-FDG helps in differentiation 
between tumor and normal brain tissue. It should be noted, 
however, that the correlation between 18F-FDG uptake and 
glucose metabolism in tumors may differ from that in normal 
tissue.97 In untreated tumor, the degree of 18F-FDG uptake has 
been correlated with tumor grade: high-grade tumors demon-
strate increased tracer uptake, and high uptake in a previously 
categorized low-grade tumor confirms anaplastic transfor-
mation of the tumor.98,99  Quantitatively, ratios of 18F-FDG 
uptake in tumors to that of white matter (.1.5) or gray matter 
(.0.6) were able to distinguish low-grade (grades I and II) 
from high-grade tumors (grades III and IV).100 Based on a 
preliminary finding, delayed imaging at 3–8 hours after injec-
tion can further distinguish tumor and normal gray matter due 
to the faster tracer excretion in normal brain than in tumor.101 
However, after therapy the degree of tracer uptake does not 
necessarily correlate with tumor grade in that high-grade 
tumors may have uptake similar to or slightly above that of 
white matter.102
18F-FDG PET also plays a role in differentiating 
between recurrent or residual tumor and radiation necrosis 
(Figures 4 and 5). However, due to the 18F-FDG uptake 
in normal brain, the sensitivity of detecting recurrent or 
residual tumor is low.103,104 The specificity is also low in the 
initial few weeks post-therapy due to radiation necrosis. 
A study showed a sensitivity of 81%–86% and a specificity 
of 40%–94% for distinguishing between radiation necrosis 
and tumor.105 It is thus recommended that 18F-FDG PET 
should not be performed before 6 weeks after the completion 
of radiation treatment.
Recently, new issues have emerged regarding the 
 evaluation of disease response, and also with the identifi-
cation of patterns such as pseudoprogression, frequently 
indistinguishable from real disease progression,106 and 
pseudoresponse. The Macdonald criteria,107 widely used 
clinically as a guideline for evaluating therapeutic response 
in high-grade gliomas, uses contrast-enhanced CT and MRI, 
and defines progression as greater than a 25% increase in size 
of enhancing tumor. Enhancement of brain tumors, however, 
primarily reflects a disturbed BBB.
By def inition, pseudoprogression of gliomas is a 
treatment-related reaction of the tumor with an increase 
in enhancement and/or edema on MRI, suggestive of 
tumor progression, but without increased tumor activity 
(Figure 6). Typically, the absence of true tumor progres-
sion is shown by a stabilization or decrease in size of the 
lesion during further follow-up and without new treatment. 
 Pseudoprogression occurs frequently after combined 
 chemo-irradiation with temozolomide, the current standard 
of care for glioblastomas.20,65
Figure 4 Tumor recurrence versus radiation induced changes: images of a 77-year-
old male who was originally diagnosed with glioblastoma multiforme, treated with 
external beam radiation and adjuvant chemotherapy with temozolomide.
Notes: Ten-month follow-up MR T1 post-contrast images (A) demonstrate a 
distinct area of enhancement (arrow) in the left temporoparietal lobe region of 
prior tumor. T2-weighted MR images (B) demonstrate hyperintense signal in the 
left parietal lobe extending to the left temporal lobe. This pathologic contrast 
enhancement is suggestive of an infiltrative mass. FDG PET only (C) and PeT-CT 
fusion images (D) demonstrate a focus of increased FDG activity corresponding to an 
enhanced area of uptake on post-contrast T1 images. These findings are consistent 
with tumor recurrence. There is also decreased tracer uptake surrounding these 
areas consistent with vasogenic edema.
Abbreviations: CT, computed tomography; FDG, 2-fluorodeoxyglucose; 
MR, magnetic resonance; PeT, positron emission tomography.
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In an effort to identify patients likely to exhibit pseudo-
progression, some studies have attempted to correlate MGMT 
promoter methylation status with pseudoprogression.20 
 Studies have demonstrated that MGMT methylation status is 
an important biomarker for assessing primary brain tumors, 
as MGMT status has been shown to correlate with both 
therapy response and OS in GBM when therapy includes 
alkylating agents.19,108 However, similar studies of MGMT 
promoter methylation in anaplastic oligodendrogliomas were 
unable to find a correlation between MGMT methylation 
status and either response rate, time-to-progression, or OS, 
suggesting that MGMT promoter methylation patterns may 
be dependent on cell type.109
Another phenomenon, pseudoresponse, is the decrease 
in contrast-enhancement and/or edema of brain tumors on 
MRI without a true antitumor effect. It occurs after treatment 
with agents that induce a rapid normalization of abnormally 
permeable blood vessels or regional cerebral blood flow.110 
Recent trials on high-grade gliomas with agents that modify 
the signaling pathways of vascular endothelial growth factor 
(VEGF), formerly also known as the vascular permeability 
factor111,112 (eg, bevacizumab, cediranib), have shown a rapid 
decrease in contrast enhancement with high response rate 
and 6-month PFS (PFS-6), but with rather modest effects 
on OS.111–113
These two opposing phenomena emphasize that 
enhancement by itself is not a measure of tumor activity, 
but only reflects a disturbed BBB. A recent case report by 
our group emphasizes the value of 18F-FDG PET when 
Figure 5 18F-FDG PeT for tumor recurrence: 71-year-old male patient with 
history of glioblastoma multiforme, status post-resection presents for evaluation 
of recurrence.
Notes: Contrast-enhanced MR T1 images (A) demonstrate a large cavity in the 
left posterotemporal-parietal junction with an irregular rim of enhancement. 
T2-weighted MR images (B) demonstrate hyperintensity in the posterotemporal 
and parietal lobes. These findings are suspicious for tumor recurrence around the 
periphery of previous location of mass in the left posterior temporoparietal region. 
(C) 18F-FDG PeT only and (D) PeT-CT fusion images demonstrate a relatively large 
area of absent 18F-FDG uptake corresponding to the cavity noted on MRi, with 
no area of abnormally increased 18F-FDG to suggest the presence of residual or 
recurrent high-grade viable tumor.
Abbreviations: CT, computed tomography; FDG, 2-fluorodeoxyglucose; MR, magnetic 
resonance; MRi, magnetic resonance imaging; PeT, positron emission tomography.
Figure 6 18F-FDG PeT diagnosis of pseudoprogression.
Notes: Patient with a history of glioblastoma, status post-resection, now after treatment with total dose of 60 Gy in 2-Gy fractions presents for a follow-up, 1 month after 
radiation therapy. MRi (A) demonstrates enhancement posterior to the prior resection cavity in the left frontal lobe (arrowhead). However, the patient showed clinical 
improvement, and therefore an 18F-FDG PeT scan was done to assess for tumor progression. On PeT (B), no abnormal areas of increased 18F-FDG uptake in the region of 
MRI contrast enhancement were identified (C), thus additional therapy was deemed not indicated; the patient was monitored on follow-up contrast-enhanced MRi scans, 
which were negative. Thus, PeT scan was helpful in differentiating pseudoprogression from true progression. Adapted with permission from Lippincott williams and wilkins/
wolters Kluwer Health: Oborski MJ, Laymon CM, Lieberman FS, Mountz JM. Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of 
current clinical practice and demonstration of the potential value of 18F-FDG PeT. Clin Nucl Med. 2013;38(5):381–384.56 Copyright © 2013. Promotional and commercial 
use of the material in print, digital or mobile device format is prohibited without the permission from the publisher Lippincott williams and wilkins. Please contact 
journalpermissions@lww.com for further information.
Abbreviations: FDG, 2-fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.
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pseudoprogression is strongly suspected by the referring phy-
sician.56 Currently, 18F-FDG PET is not a clinically standard 
method for evaluating therapeutic response in high-grade 
gliomas, as it is only used for initial staging and to confirm 
suspected recurrence observed on gadolinium MRI (Gd-
MRI). However, a central advantage of 18F-FDG PET is that it 
can be used to determine the metabolic state of tumor cells, in 
contrast to Gd-MRI, which is limited to evaluating changes in 
size of contrast enhancement. This is an important distinction 
in comparing 18F-FDG PET and Gd-MRI results, as changes in 
contrast enhancement are generally a conglomeration of many 
effects, such as local vascularity, changes in both normal and 
tumor cell density, necrosis, apoptosis, and BBB breakdown. 
All of these morphological changes are presumably preceded 
by changes in tumor metabolism, suggesting that, in many 
cases, 18F-FDG PET may allow for comparatively faster dis-
crimination of pseudoprogression from true progression and 
pseudoresponse from true response.
Recent efforts have focused on the coregistration of PET 
and MRI images, which has increased sensitivity over using 
either modality alone.114,115 The simultaneous PET–MRI scan, 
which offers better MRI-based motion correction of PET 
data, is also being studied in more centers.116,117
Amino acid PeT tracers
Amino acid and amino acid analog PET tracers are better suited 
than 18F-FDG for quantitative monitoring of tumor response due 
to higher tumor-to-normal-tissue contrast.118–122 The use of amino 
acids for tumor imaging is based on the observation that amino 
acid transport is upregulated in malignant transformation.123,124 
Response after chemotherapy can be detected by amino acid 
PET early in the course of treatment,125–127 suggesting that deac-
tivation of amino acid transport is an early sign of response to 
chemotherapy. Amino acids are transported across the cell via 
a carrier-mediated mechanism.128 For example, transport of the 
18F amino acid analog 3-O-methyl-6-18F-fluoro-L-DOPA via 
sodium- independent, high-capacity amino acid transport sys-
tems has been demonstrated in tumor cell lines.129 In gliomas, 
increased amino acid uptake is mediated by type L amino acid 
carriers, which are upregulated in tumor vasculature.124,130 This 
is in part attributed to the increased metabolic demand of tumor 
cells. Several amino acid tracers are available, though they 
are not FDA-approved in the US; eg, O-(2-18F-fluoroethyl)-L-
tyrosine (FET), 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine, 
and of 11C methionine (MET).131,132
MET: The best-studied PET amino acid isotope has been 
l-[methyl-11C] methionine (11C-MET),133 which is able to 
differentiate tumor recurrence from radiation necrosis.134 
However, due to the relatively short 11C half-life of 20 
minutes, it requires a nearby cyclotron. The extent of tracer 
uptake is greater than the degree of contrast enhancement 
indicative of better delineation of tumor margins.135 In low-
grade gliomas, the uptake is increased in the absence of 
BBB breakdown, which is a significant advantage over CT, 
conventional MRI, and 18F-FDG PET.136,137 The tracer uptake 
has been shown to correlate with prognosis and survival in 
low-grade gliomas.138,139 In high-grade gliomas, 11C-MET 
uptake is greater than in low-grade tumors,140–142 establishing 
its potential for use in monitoring anaplastic transformation. 
In fact, recent findings show that increased 11C-MET uptake 
during tumor growth parallels an upregulation of angiogenic 
markers such as VEGF.143 Moreover, the addition of 11C-MET 
PET changed patient management in half the cases.144
18F-FET (fluoro-3′-deoxy-3′-l-fluorothymidine) is another 
PET tracer studied for its potential role in the differen-
tiation of radiation necrosis and residual tumor. Indeed, the 
absence of 18F-FET uptake in a case of radiation necrosis 
was shown,131 but further systematic studies are necessary to 
confirm this finding. In contrast to 18F-FDG, 18F-FET uptake 
was absent from macrophages, a common inflammatory 
mediator.145 In another study, the ratio of 18F-FET uptake in 
radiation necrosis to that in normal cortex was much lower 
than the corresponding ratios for 18F-FDG and 18F choline, 
supportive of its potential for differentiating radiation necro-
sis from tumor recurrence.146
In the last decade, studies on combined 18F-FET and 
MRI have shown improved identification of tumor tissue 
as compared with either modality alone.147,148 The specific-
ity of distinguishing gliomas from normal tissue could be 
increased from 68% with the use of MRI alone to 97% with 
the use of MRI in conjunction with 18F-FET PET and MRI 
spectroscopy.149
Nucleic acid analogs – 18F-FLT
The pyrimidine analog, 18F-FLT, is a PET radiotracer spe-
cifically used for noninvasive in vivo evaluation of the cell 
proliferation rate. 18F-FLT reflects the activity of thymidine 
kinase-1 during phase S of DNA synthesis.150 18F-FLT, intro-
duced by Shields et al for PET imaging of tumor proliferation 
in animals and humans,151 has been used in both preclinical 
and clinical studies.152,153 Transport of 18F-FLT is medi-
ated by both passive diffusion and Na+-dependent carriers. 
The tracer is subsequently phosphorylated by thymidine 
kinase 1 (TK
1
) into 18F-FLT-monophosphate, where TK
1
 is a 
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principal enzyme in the salvage pathway of DNA synthesis. 
Whereas the TK
1
 activity is virtually absent in quiescent cells, 
its activity reaches the maximum in the late G
1
 and S phases 
of the cell cycle in proliferating cells.154 The phosphorylation 
of the tracer by TK
1,
 therefore, makes 18F-FLT a good marker 
for tumor proliferation.
Recent findings suggest that 18F-FLT is a promising 
biomarker for differentiating between radiation necrosis and 
tumor recurrence (Figure 7).155,156 A study by Hatakeyama 
et al155 showed its superiority over 11C-MET in tumor grading. 
Chen et al demonstrated 18F-FLT PET as a promising imaging 
biomarker that seems to be predictive of OS in bevacizumab 
and irinotecan treatment of recurrent gliomas in which both 
early and later 18F-FLT PET responses were more signifi-
cant predictors of OS compared with the MRI responses.157 
In addition, a recent prospective study by Schwarzenberg 
et al158 showed that 18F-FLT uptake was highly predictive of 
PFS and OS in patients with recurrent gliomas on bevaci-
zumab therapy (Avastin®; Genentec, South San Francisco, 
CA, USA; a recombinant humanized monoclonal antibody 
targeting VEGF, a protein released by tumor cells to recruit 
novel blood vessels to support tumor growth),159,160 and that 
18F-FLT PET seems to be more predictive than MRI for early 
treatment response.
Hypoxia imaging – 18F-fluoromisonidazole
18F-Fluoromisonidazole is a nitroimidazole derivative PET 
agent used to image hypoxia,161 a physiologic marker for tumor 
progression and resistance to radiotherapy (RT).162 Its prefer-
ential uptake in high-grade rather than low-grade gliomas,163 
a significant relationship with upregulation of angiogenic 
markers such as VEGF receptor 1,164 and correlation to pro-
gression and survival after RT,165 suggest its potential role in 
monitoring response to therapy targeting hypoxic tissue.
Biopsy
A tissue diagnosis can be obtained at the time of surgical 
resection or through stereotactic biopsy. Biopsy alone is used 
in situations where the lesion is not amenable to resection, 
or when a meaningful amount of tumor tissue cannot be 
resected, or the patient’s overall clinical condition will not 
permit invasive surgery.
Stereotactic image-guided brain biopsy is an accurate and 
safe diagnostic procedure in patients with focal lesions.166,167 
The combined use of computerized imaging and stereotactic 
framing devices allows neurosurgeons to perform deep brain 
biopsies with continuous and accurate intraoperative tumor 
localization. Frameless stereotaxy establishes a computerized 
link between the preoperative three-dimensional tumor vol-
ume and the surface landmarks of the patient. This link per-
mits the neurosurgeon to be aware of the three-dimensional 
position of surgical instruments within the intracranial space 
during the biopsy based upon the preoperative imaging, with 
an accuracy of 1 mm within the intracranial space.
Treatment
After decades of minimal incremental advances in out-
comes for multimodality treatment of malignant gliomas, 
the last decade has seen a series of transformative clinical 
trials establish new standards of care. At the same time, the 
A
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Figure 7 18F-FLT PeT.
Notes: Sixty-five-year-old female who initially presented with glioblastoma multiforme, now presents after completion of 6 weeks of temozolomide chemotherapy and a total 
of 60 Gy radiotherapy to the tumor. T1 post-contrast enhanced images (A) demonstrate slight progression as compared to prior study. However, FLT uptake post-therapy 
(C) was significantly decreased as compared to baseline scan (B). This finding was suggestive of a response to therapy.
Abbreviations: FLT, fluoro-3′-deoxy-3′-l-fluorothymidine; PET, positron emission tomography; SUV, standardized uptake value.
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limitations of these transformative strategies have raised new 
questions for therapeutic clinical trials. Addressing these 
questions requires innovative neuroimaging strategies to bet-
ter assess treatment response. The application of molecular 
neuropathology, quantitative imaging of tumor response, 
and systematic evaluation of molecularly targeted therapies, 
as well as cytotoxic chemotherapy are expected to improve 
outcomes even further.
Surgery
Surgical resection has been a critical component of the multi-
modality management of malignant gliomas since the advent 
of modern neurosurgery and the original case series by Cush-
ing and Dandy.168 The role of neurosurgery has expanded in 
recent years to include techniques for intratumoral delivery 
of drugs, monoclonal antibodies, viral gene vectors, and 
immunotherapeutics. Resection or image-guided techniques 
for accessing the tumor microenvironment are increasingly 
critical components of therapeutic clinical trials as they help 
to show drug delivery to the tumor site and to verify that the 
anticipated physiologic effects relevant to the mode of action 
of the drug have occurred.169,170 In the era of molecularly-
targeted therapies and personalized therapeutics, determina-
tion of the pattern of genetic and epigenetic changes in tumor 
tissue is critical to understanding the mechanisms of tumor 
response and resistance.171
For GBM patients, there is compelling, though not level-
one evidence, that maximal resection of newly diagnosed 
tumor improves survival.172–174 For anaplastic astrocytoma 
and anaplastic oligodendrogliomas, the survival benefit of 
aggressive surgical resection is less clearly documented, 
but expert consensus supports similar resection goals as for 
GBM patients.175 Maximal surgical resection provides the 
advantages of rapid cytoreduction, relief of symptoms related 
to mass effect, allows for institution of fractionated radiation 
therapy and chemotherapy with reduced target volumes, and 
provides tissue for diagnosis.168
Image-guided resection and the incorporation of functional 
MRI information as well as intraoperative mapping has allowed 
for resection of tumors in close proximity to eloquent cortical 
structures and expanded the indications for resection.176–181 
Innovations in MRI design have allowed for intraoperative 
MRI, in which the neurosurgeon can assess completeness of 
resection prior to closure of the craniotomy.
Minimally invasive neurosurgical techniques, exemplified 
by endoscopic resection techniques182 are being applied to 
resection of malignant gliomas, facilitating more complete 
resection of deeply located tumors, and intraventricular 
or periventricular tumors.183 Neurosurgical techniques for 
intratumoral drug delivery are also being investigated. 
 Stereotactic MRI or CT-guided techniques allow for biopsy 
and intratumoral delivery of therapeutic agents, though 
limited capacity for diffusion limits this technique in most 
settings. Microdialysis catheters placed at the time of tumor 
resection allow direct measurement of drug pharmacodynam-
ics in clinical trials of systemically administered agents.
RT
Shortly after the initial attempts to control malignant 
gliomas with aggressive surgical resection, neurosurgeons 
and oncologists turned to EBRT as the second component 
of multimodality therapy. Seminal clinical trials by the early 
brain tumor clinical trial collaborative groups demonstrated 
that EBRT prolongs survival as compared with surgery 
alone, for GBM, anaplastic astrocytoma, and anaplastic 
oligodendrogliomas.184–186 Collaborative group trials estab-
lished optimal dose and fractionation schema for the different 
histologies and grades of malignant tumors.
Involved field radiation therapy, which involved delivery 
of RT only to involved regions of the brain, has become the 
standard approach for adjuvant RT. The rationale for limiting 
the RT field is based upon the observation that, following 
whole brain radiation therapy, recurrent malignant gliomas 
develop within 2 cm of the original tumor site in 80%–90% 
of cases, while fewer than 10% are multifocal.187–189 To 
encompass infiltrating tumor cells, the RT dose of typically 60 
Gray is usually delivered to the tumor plus a margin of radio-
graphically apparently normal tissue. If the tumor is defined 
based upon contrast enhancement, a margin of 2.0 to 3.0 cm 
is often used, while if the RT field is defined by T2-weighted 
MRI abnormality, a 1.0 to 2.0 cm margin is used.
Over the past 3 decades, innovations in computer-based 
three-dimensional treatment planning have led to an increase 
in conformal radiation therapy. In academic centers of excel-
lence, as well as in the community, these techniques have 
provided a new approach to treat malignant gliomas using an 
increased dose with less morbidity.  Current three-dimensional 
conformal radiation therapy utilizes CT-based treatment plan-
ning with dosimetric software to create composite treatment 
plans. The fusion of planning CT with MRI is extremely help-
ful in assisting with target definition.190,191 The incorporation 
of PET or MRS data is still largely investigational and most 
commonly used to define boost volumes rather than primary 
target volumes. Photons of 6 to 8 MV are most commonly 
used with three to four angled radiation fields. Radiation 
oncologists work with medical physicists and dosimetrists 
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to design optimal treatment plans. Optimization requires 
the consideration of beam energy, field size and shape, 
beam modifiers, irradiated tissue density and heterogeneity, 
and radiation tolerance of surrounding normal tissues. No 
benefit in PFS or OS has been demonstrated, although these 
techniques help avoid excess RT to normal brain.192,193
In the past several years, intensity-modulated radiation 
therapy (IMRT), at least for academic radiation oncology 
centers, has been the technique of choice due to the elegance 
and precision of the dosimetry, especially if the tumor is in 
close proximity to radiosensitive structures such as the optic 
nerve. The IMRT technique uses advanced technology to 
manipulate beams of radiation to conform to the shape of a 
tumor. It uses nonuniform small radiation beams of varying 
intensities to deliver a treatment plan that maximizes the 
homogenous delivery of radiation to the intended treatment 
volume, while minimizing irradiation to normal tissue outside 
the target. The radiation intensity of each beam is controlled, 
and the beam shape changes throughout each treatment. 
The goal of IMRT is to bend the radiation dose to avoid or 
reduce exposure of healthy tissue and limit the side effects 
of treatment. The application of IMRT in the treatment of 
malignant gliomas has become increasingly prevalent as it 
may decrease radiation-related adverse effects.194 IMRT can 
also be used to escalate doses to the tumor, but there are 
no proven benefits to delivering doses beyond 60 Gray.195 
The most appropriate application of IMRT in the brain will 
likely be when the radiation target abuts radiation-sensitive 
structures such as the eyes, optic nerves, optic chiasm, or 
brainstem. The disadvantages of IMRT include increased 
radiation scattering to surrounding non-target tissues and the 
complexity of radiation planning, which requires adaptation 
of the hardware of linear accelerators, skilled physicist sup-
port, and increased delivery time for treatment.
Despite decades of trials investigating permutations of 
total dose and fractionation schemes, the typical one per day 
treatment with external beam, 5 days per week, has remained 
the standard of care. With present technologies and strate-
gies for radioprotection of normal structures, improvements 
in survival are unlikely to result from modifications in total 
dose or fraction size.
Proton beam RT is being investigated in the treatment 
of low-grade gliomas, medulloblastomas and ependymo-
mas, and in malignant gliomas. At present, there is no 
level-one evidence that proton beam therapy improves 
survival in either the newly diagnosed or recurrent setting 
for GBM or anaplastic astrocytoma and oligodendroglioma. 
As with IMRT, proton techniques may have a specialized 
role in treatment of targets close to critical radiosensitive 
structures.
Stereotactic radiosurgery has been used to boost fraction-
ated RT for the treatment of newly diagnosed GBM following 
either biopsy or resection.196–198 Stereotactic radiosurgery 
uses three-dimensional planning techniques to precisely 
deliver narrowly collimated beams of ionizing radiation in 
a single high-dose fraction to small (,4 cm) intracranial 
targets. When this approach is divided into several factions 
it is called stereotactic RT.
In some centers, Gamma Knife radiosurgery is used, 
in which a hemispherical compartment with an array of 
cobalt-60 sources is the source of collimated beams. The 
Gamma Knife uses a fixed frame to stabilize the head relative 
to the radiation sources.
Frameless linear-accelerator-based stereotactic radiosur-
gery employs a linear accelerator that moves in multiple arcs 
around the target volume. The linear accelerator techniques 
do not employ a fixed frame, and the relationship of the target 
volume to the radiation source is determined by registration 
of fiducials.
Radiosurgery has transformed the treatment of brain 
metastasis and benign tumors such as acoustic schwannoma, 
but has yet to claim a clear role in the treatment of malignant 
gliomas.199–202 In the newly diagnosed setting, radiosurgery 
in conjunction with fractionated EBRT has not improved 
survival outcomes. However, in the recurrent setting, 
radiosurgery is an FDA-approved treatment modality, but 
progression at the margin of the target is a ubiquitous pattern 
of failure. More recently, radiosurgery has been combined 
with bevacizumab therapy. Initial institutional Phase II 
trials of this combination have not demonstrated superior 
time-to-progression or OS than either treatment alone, but 
some patients have durable tumor control.203 The nuances in 
designing treatment fields may be critical in this setting.204
Chemotherapy/drug therapy
The current standard of care for newly diagnosed GBM 
combines surgical resection, RT and adjuvant temozolomide 
treatment, leading to an increased median survival time205 of 
approximately 14.6 months. The EORTC trial206 established 
that concomitant low-dose temozolomide and external beam 
fractionated radiation followed by adjuvant temozolomide 
results in a survival benefit to the chemotherapy arm versus 
radiation alone. The trial demonstrated a benefit in OS to the 
group receiving chemotherapy, and a tripling of the percentage 
of patients alive 2 years after therapy. Subsequent prospective 
trials showed that a dose-intensive adjuvant temozolomide 
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regimen in which patients received 75 mg/m2 daily for 21 
days followed by a 7-day rest was not superior to the shorter 
monthly courses of temozolomide.
Management of newly diagnosed anaplastic oligodendro-
glioma is now based on level-one evidence. Two prospective 
randomized trials comparing external beam radiation alone 
to radiation therapy plus alkylator-based adjuvant or neoad-
juvant chemotherapy were initially reported as showing no 
survival benefit with the addition of chemotherapy.11,13 How-
ever, long-term follow-up demonstrated that for patients with 
tumors expressing 1p/19q deletions, chemotherapy confers a 
significant survival advantage.11,13 The predictive value of the 
1p deletion status makes this one of the first robust predictive 
biomarkers for malignant gliomas. In addition to the impact 
of 1p deletion status on outcome, these anaplastic oligoden-
droglioma studies also led to the delineation of subgroups 
of tumors with prognostic significance using microarray 
genome-wide expression analysis.207 It is clear that future 
studies of anaplastic oligodendrogliomas and astrocytomas 
will need to include stratification by prognostic subgroups.
For newly diagnosed anaplastic astrocytoma, the optimal 
application of radiation and chemotherapy is an active clini-
cal trial question.208 The EORTC and the Radiation Therapy 
Oncology Group (RTOG) are conducting a randomized 
prospective trial comparing fractionated radiation therapy 
alone, to 1) radiation followed by adjuvant temozolomide, 
to 2) concurrent chemoradiation without subsequent adjuvant 
therapy, and to 3) the regimen of concurrent chemoradiation 
followed by adjuvant chemotherapy that is the standard treat-
ment for GBM.209,210 In addition, these prospective random-
ized trials are stratifying tumors based on MGMT promoter 
methylation status and molecular biomarkers.208
For patients with recurrent GBM, treatment outcomes 
are poor; the median time to tumor progression is 9 weeks, 
and the median survival is 25 weeks.211 PFS is correlated 
with OS and has become the benchmark for assessing treat-
ment efficacy in patients with recurrent GBM in whom the 
PFS-6 rate ranges between 9% and 15%.211–213 For recurrent 
GBM and anaplastic astrocytoma, the transformative trials 
involve the use of anti-angiogenic drugs.214 The RTOG has 
completed two prospective randomized trials; one comparing 
two different adjuvant temozolomide regimens and another 
evaluating the efficacy of bevacizumab.215,216
Glioblastomas due to expression of a variety of pro-
 angiogenic factors are among the most vascular tumors. 
Angiogenesis is a critical process in the progression of 
gliomas.217 One of the main determinants of angiogenesis 
is VEGF, which is secreted by glioma cells to induce the 
tumor vascularization that in turn facilitates growth of the 
tumor.218 High expression of VEGF is correlated with poor 
clinical outcome, and it has been demonstrated that inhibition 
of VEGF decreases the growth of glioma cell lines.219 High-
grade gliomas with a high degree of VEGF expression and 
vessel density respond best to anti-angiogenic therapy.220
Bevacizumab is an anti-angiogenic agent for GBM and 
received accelerated FDA approval for use in patients with 
recurrent GBM in 2009.221 Bevacizumab (Avastin) is a 
humanized monoclonal antibody that binds VEGF, thereby 
preventing the interaction of VEGF with its receptors 
VEGF receptor 1 and VEGF receptor 2. Blocking VEGF 
activity halts angiogenesis. The half-life of bevacizumab is 
approximately 20 days, so it is administered every 2 weeks 
and sometimes every 3 weeks. In Phase II studies in previ-
ously treated patients with malignant glioma, bevacizumab 
reduced requirements for steroids and was associated with 
imaging evidence of tumor response. These results have led 
to approval of bevacizumab for recurrent malignant glioma 
as well as investigation of bevacizumab as a component of 
initial combined modality therapy.222
Bevacizumab has demonstrated significant activity in 
Phase II trials.221 Bevacizumab alone or in combination 
with irinotecan resulted in response rates and time-to-
progression that were substantially superior to historical 
controls with a range of cytotoxic regimens, and superior 
to results with any other molecularly-targeted drug therapy 
evaluated previously.223 However, the value of bevacizumab 
in the treatment of recurrent GBM remains uncertain since 
responses in GBM trials have not been durable. Norden 
et al224 compared PFS and OS of patients treated with 
bevacizumab with two contemporaneous trials of cytotoxic 
chemotherapy testing gimatecan and edotecarin. Median 
PFS in the bevacizumab cohort was 22 weeks, compared 
to only 8 weeks for the chemotherapy cohorts, and PFS-6 
was 40% versus 11%. However, median OS was only 37 
weeks in the bevacizumab cohort versus 39 weeks for the 
chemotherapy cohorts.224 Bevacizumab appears to have 
an effect on PFS, but only modest effects on OS.225 When 
patients progress through bevacizumab, the prognosis is 
dismal, with PFS of subsequent therapies being 4 weeks 
and PFS-6 being only 14%.226,227  Current and future trials 
evaluating combination therapies with molecularly-targeted 
drugs and bevacizumab have evolved a template structure 
in which bevacizumab is administered every 2 weeks in 
28-day cycles, and the investigational agent is added to the 
monthly cycles with the scheduling dependent upon the 
biologic effect of the agent.
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Although bevacizumab clearly produces a clinical 
improvement by decreasing the size of the contrast-enhancing 
mass lesion as well as ameliorating perilesion edema, the 
extent to which the drug is modifying the physiology of 
the BBB rather than killing tumor cells remains complex. 
When tumors progress after exposure to bevacizumab, sub-
sequent therapies with cytotoxic chemotherapy are uniformly 
 ineffective. In current practice, there is an emerging consensus 
that bevacizumab should be reserved for patients in whom 
the tumor is causing neurologic symptoms due to its size and 
surrounding edema.228 The ability of bevacizumab to sup-
press the early toxicities of radiation therapy has facilitated 
re-exploration of reirradiation with fractionated external beam 
techniques as well as radiosurgery for recurrent malignant 
gliomas. Several institutional trials229,230 have reported results 
of combining radiosurgery with Avastin in recurrent GBM 
and anaplastic astrocytoma. Although bevacizumab clearly 
reduces the early perilesion edema associated with radiosur-
gical treatment of recurrent malignant gliomas and produces 
radiologic responses by RANO criteria, it remains unproven 
whether the combination of radiosurgery and Avastin produces 
a more durable response, as measured by OS, than radiosur-
gery or bevacizumab alone.
Preliminary randomized Phase III trial results do not 
recommend the routine use of bevacizumab in combination 
with standard RT and temozolomide in patients with newly 
diagnosed glioblastoma.231,232 This recommendation is based 
on the lack of proven survival benefit for bevacizumab when 
used as part of initial therapy and the increased risk of toxic-
ity associated with combination therapy. Certain subsets of 
patients may ultimately be shown to benefit from early use of 
bevacizumab, such as those patients with bulky, nonresectable 
tumors, but further study is needed. Preliminary results from 
two Phase III clinical trials231,232 assessing the role of bevaci-
zumab in conjunction with RT plus temozolomide include the 
AVAglio study, in which 921 patients were randomly assigned 
to receive bevacizumab or placebo in conjunction with RT 
and temozolomide.231 After completion of RT, patients were 
treated with six cycles of monthly temozolomide plus beva-
cizumab or placebo every 2 weeks, followed by maintenance 
bevacizumab or placebo every 3 weeks until progression. At 
the time of the preliminary analysis, 76% of the expected 
events had occurred. They concluded that median PFS was 
improved in patients treated with bevacizumab compared 
with placebo (10.6 versus 6.2 months; hazard ratio 0.64, 
95% confidence interval 0.55 to 0.74). However, median OS 
was not significantly different (hazard ratio 0.89, 95% confi-
dence interval 0.75 to 1.07). As well, there was an increase 
in the rate of serious adverse events in patients treated with 
bevacizumab.
In the RTOG 0825 study, 637 patients were randomly 
assigned to receive bevacizumab or placebo starting at week 
4 of standard chemoradiation with temozolomide, followed 
by six to 12 cycles of maintenance temozolomide plus 
bevacizumab or placebo.232 The conclusion was that PFS was 
extended in patients treated with bevacizumab (10.7 versus 7.3 
months; P=0.004), but the result did not meet the predefined 
significance threshold of P,0.002. Median OS did not differ 
in patients treated with bevacizumab compared with placebo 
(15.7 versus 16.1 months, P=0.11). Notably, MGMT promoter 
methylation was strongly associated with improved PFS (14 
versus 8 months for methylated versus unmethylated promoter, 
respectively) and OS (23 versus 14 months, respectively). In 
the subset of patients whose tumors exhibited both MGMT 
promoter methylation and a favorable nine-gene signature, 
there was a trend towards worse survival in patients treated 
with bevacizumab compared with placebo (15.7 versus 25 
months, P=0.08). In addition, there was an increased rate of 
serious adverse events in patients treated with bevacizumab; 
primarily neutropenia, hypertension, and thromboembolism.
For recurrent anaplastic astrocytomas, the optimal che-
motherapy regimens remain an active clinical trial question. 
A randomized prospective trial233 for anaplastic astrocytomas 
at first relapse after fractionated RT alone compared the 
older regimen PCV to standard (150–200 mg/m2/day for 
days 1–5 of 28-day cycles) temozolomide and dose-intensive 
temozolomide (75 mg/m2/day for days 1–21 of 28-day 
cycles). The day 1–5 regimen was not inferior to PCV, but 
the more dose-intense regimen was counterintuitively less 
effective. The optimal regimens for patients relapsing after 
prior chemoradiation or adjuvant chemotherapy remain to 
be determined.
For recurrent anaplastic oligodendrogliomas, alkylator-
based chemotherapy is the mainstay of treatment, but as for 
astrocytomas, the optimal regimen and schedules are cur-
rently being pursued.12,234–236 A study by Lassman12 of ana-
plastic oligodendrogliomas suggest that for 1p/19q deleted 
tumors, the older PCV regimen may be associated with better 
outcomes. Despite this retrospective data, temozolomide 
continues to be more widely used in the US.
Despite a quarter century of disappointing results and 
evidence that the malignant gliomas microenvironment was 
inhospitable to cytotoxic T cells and natural killer cells, a 
relentless cadre of investigators has produced Phase II data 
suggesting that vaccine immunotherapy strategies can pro-
duce antitumor immune responses.237 In a study of newly 
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diagnosed GBM tumors expressing the EGFRvIII oncoprotein 
antigen, an anti-EGFRviii dendritic cell vaccine demonstrated 
improved time-to-progression and OS as compared with a 
contemporaneous historical control data set.238 With all the 
caveats pertaining to historical control analysis and potential 
differences in distribution of molecular prognostic subgroups, 
vaccine therapies are demonstrating sufficient evidence of 
efficacy to warrant Phase III trials. As with clinical trials 
evaluating anti-angiogenic agents, criteria for determining 
tumor response and progression must be adapted to account 
for transient immune-mediated inflammatory responses that 
might be mistaken for development of tumor progression.239
Summary
In recent times, there has been important progress in our 
understanding of the molecular pathogenesis of malignant 
gliomas, leading to the development of targeted chemothera-
peutic agents. Additionally, advances in diagnostic imaging 
have allowed for early diagnosis and treatment of malignant 
gliomas. As our understanding of the molecular pathogenesis 
and molecular imaging improves, it may be possible to select 
the most appropriate therapies on the basis of the patient’s 
tumor genotype. Furthermore, quantitative imaging biomarker 
assessment in the early phase of clinical trials could provide a 
novel approach for testing new therapies, and importantly, for 
facilitating patient management, sparing patients from weeks 
or months of toxicity due to ineffective treatment.
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